Pathophysiology and Diagnosis of Chronic Liver Disease

Aisha Shabbir; Misbah Arshad; Ali Junaid Dar; Sidra Khalid

doi:10.54393/pjhs.v2i01.22

Authors

Aisha Shabbir University College London, London, United Kingdom
Misbah Arshad University Institute of Dietetics and Nutritional Sciences, Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
Ali Junaid Dar Faculty of Allied Health Sciences, The University of Lahore, Gujrat Campus, Pakistan
Sidra Khalid Lahore Medical Research Center, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v2i01.22

Keywords:

Chronic liver disease, Pathophysiology, Bio-markers, Fibrosis, Aspartate Transaminase

Abstract

Chronic liver disease (CLD) is caused by an inflammatory damage to the liver that lasts six months or more. The development of new blood vessels, regardless of the underlying aetiology, is a fundamental process in the pathogenesis of chronic liver diseases (CLDs). Given the fact that CLDs often advance from hepatocyte injury to inflammation, fibrosis, cirrhosis, and, in rare circumstances, hepatocellular cancer, CLDs cannot be regarded a single illness (HCC). Neovascularisation and the creation of an aberrant angioarchitecture are linked in the pathological course of CLDs. Asymptomatic individuals with modestly increased liver enzymes such as Alanine Transaminase (ALT) and Aspartate Transaminase (ALT) are frequently found in basic care. Biochemical indicators include serum bilirubin, alanine amino transferase, aspartate amino transferase, aminotransferase ratio, alkaline phosphatase, gamma glutamyltransferase, 5' nucleotidase, ceruloplasmin, and alpha-fetoprotein. In conclusion, further epidemiological and pathophysiology research is needed. A better knowledge of the molecular pathways behind geriatric chronic liver disease will aid in determining the best diagnostic and treatment strategy for each older patient.

References

Moon, A. M., Singal, A. G., & Tapper, E. B. (2020). Contemporary epidemiology of chronic liver disease and cirrhosis. Clinical Gastroenterology and Hepatology, 18(12), 2650-2666. https://doi.org/10.1016/j.cgh.2019.07.060.

European Association for the Study of the Liver. (2019). EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of hepatology, 70(1), 172-193. https://doi.org/10.1016/j.jhep.2018.06.024.

Kovalic, A. J., Satapathy, S. K., & Thuluvath, P. J. (2020). Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatology international, 1-9. https://doi.org/10.1007/s12072-020-10078-2.

Fernandez-Varo, G. (2012). [Serological markers of fibrosis]. Gastroenterol Hepatol, 35 Suppl 2, 10-16. doi: 10.1016/S0210-5705(12)70044-4.

Caballeria, L., & Toran, P. (2012). [Early detection of chronic liver disease in primary care in the apparently health adult population]. Gastroenterol Hepatol, 35 Suppl 2, 23-29. doi: 10.1016/S0210-5705(12)70046-8.

Kim, H. J. O., S. W.Kim, D. J.Choi, E. Y. (2009). Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. [Comparative Study].

Singal, A. K., & Mathurin, P. (2021). Diagnosis and treatment of alcohol-associated liver disease: A review. Jama, 326(2), 165-176. doi:10.1001/jama.2021.7683.

Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., ... & El-Serag, H. B. (2018). Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology, 155(6), 1828-1837. https://doi.org/10.1053/j.gastro.2018.08.024.

Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020). Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology, 71(3), 907-916. https://doi.org/10.1002/hep.30858.

Kovalic, A. J., Satapathy, S. K., & Thuluvath, P. J. (2020). Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatology international, 1-9. https://doi.org/10.1007/s12072-020-10078-2.

Leon, D. A., & McCambridge, J. (2006). Liver cirrhosis mortality rates in Britain, 1950 to 2002. [Comment Letter]. Lancet, 367(9511), 645. doi: 10.1016/S0140-6736(06)68250-0.

Kim, G. A., Lee, H. C., Choe, J., Kim, M. J., Lee, M. J., Chang, H. S., ... & Lim, Y. S. (2018). Association between non-alcoholic fatty liver disease and cancer incidence rate. Journal of hepatology, 68(1), 140-146. https://doi.org/10.1016/j.jhep.2017.09.012.

Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020). AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology, 158(6), 1822-1830. https://doi.org/10.1053/j.gastro.2019.12.053.

Solanki, S. G., Patel, N. D., & Patel, P. J. Etiological Spectrum of cirrhosis in anand district, Gujrat, India. Alcohol, 105, 34-53.

Calvaruso, V., Ferraro, D., Licata, A., Bavetta, M. G., Petta, S., Bronte, F., ... & Di Marco, V. (2018). HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals. Journal of viral hepatitis, 25(1), 72-79. https://doi.org/10.1111/jvh.12754.

Hartleb, M., & Gutkowski, K. (2012). Kidneys in chronic liver diseases. [Editorial Review]. World J Gastroenterol, 18(24), 3035-3049. doi: 10.3748/wjg.v18.i24.3035.

Elizabeth Corwin, M., Ph.D., FNP. (2000). Handbook of Pathophysiology.

Yang, Y. M., Kim, S. Y., & Seki, E. (2019, February). Inflammation and liver cancer: molecular mechanisms and therapeutic targets. In Seminars in liver disease (Vol. 39, No. 01, pp. 026-042). Thieme Medical Publishers. DOI: 10.1055/s-0038-1676806.

Oh, R. C., & Hustead, T. R. (2011). Causes and evaluation of mildly elevated liver transaminase levels. Am Fam Physician, 84(9), 1003-1008.

Radwan, H. A., Elsayed, E. H., & Saleh, O. M. (2019). Significance of serum adiponectin and insulin resistance levels in diagnosis of Egyptian patients with chronic liver disease and HCC. Asian Pacific journal of cancer prevention: APJCP, 20(6), 1833. https://dx.doi.org/10.31557%2FAPJCP.2019.20.6.1833.

Green, R. M., & Flamm, S. (2002). AGA technical review on the evaluation of liver chemistry tests. [Review]. Gastroenterology, 123(4), 1367-1384.

de Avelar, C. R., Pereira, E. M., de Farias Costa, P. R., de Jesus, R. P., & de Oliveira, L. P. M. (2017). Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis. World journal of gastroenterology, 23(27), 5004. https://dx.doi.org/10.3748%2Fwjg.v23.i27.5004.